EXTON, Pa., July 25, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the second-quarter 2024 and updated full-year 2024 financial guidance. To participate in the conference call by asking questions to Management, please register in advance by clicking here. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that will be used to access the call. | --- | --- | --- | --- | --- | --- | --- | - ...

Q2 Estimates Factors to Note However, destocking, as well as the timing of new high-value product (HVP) device capacity and customer-led HVP upgrade, is likely to have led to a decline in second-quarter sales. Moreover, a weak pharma market and declining sales related to COVID-19 vaccines are expected to have offset growth in other products. The company is also expected to have witnessed a gross margin expansion in the aforementioned segment. This was likely due to a favorable mix of products sold (stemming ...

EXTON, Pa., July 11, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release second-quarter financial results before the market opens on Thursday, July 25, 2024, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. Management will refer to a slide presentation during the call, which will be made available on the day of the ...

First-Quarter 2024 | --- | --- | |-----------------------------------|--------------------------------------------| | $695.4M | First Quarter Overall Net Sales \| 3.0% | | | | | Diluted Earnings Per Share: $1.55 | Adjusted Diluted Earnings Per Share: $1.56 | WST Q1 2024 Earnings 1 "We had a solid start to the year and our full-year 2024 financial outlook remains unchanged. We are actively managing the timing of inventory decisions by some of our customers, and our recent order trends reinforce our prior out ...

West Pharmaceutical Services, Inc. (NYSE:WST) Q1 2024 Earnings Conference Call April 25, 2024 9:00 AM ET Company Participants Quintin Lai - Vice President, Strategy and Investor Relations Eric Green - President and Chief Executive Officer Bernard Birkett - Senior Vice President, Chief Financial and Operations Officer Conference Call Participants Matt Larew - William Blair Jacob Johnson - Stephens Paul Knight - KeyBanc Michael Ryskin - Bank of America Justin Bowers - Deutsche Bank David Windley - Jefferies ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-8036 WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 23-1210010 (State or o ...

Exhibit 99.1 West Announces First-Quarter 2024 Results and Declares Third-Quarter 2024 Dividend - Conference Call Scheduled for 9 a.m. EDT Today - Exton, PA, April 25, 2024 – West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the first-quarter 2024 and updated full-year 2024 financial guidance. First-Quarter 2024 Summary (comparisons to prior-year period) "Adjusted-diluted EPS" and "organic sales growth" are Non-U.S. GAAP measurements. See discussion under the heading " ...

Customer Concentration - The company's ten largest customers accounted for 41.4% of consolidated net sales in 2023, with one customer contributing 10.9% or $322.1 million[34] - In 2023, the company's ten largest customers accounted for 41.4% of consolidated net sales, with one customer contributing 10.9% or $322.1 million[34] Intellectual Property - In 2023, more than 190 patents were issued globally, indicating a strong focus on intellectual property development[27] - The company was issued more than 190 patents globally in 2023, indicating a strong focus on intellectual property development[27] Workforce and Employment - The company employed approximately 10,600 people as of December 31, 2023, with a hiring of 2,100 new team members during the year and an attrition rate of approximately 21%[43] - The company employed approximately 10,600 people as of December 31, 2023, with a hiring of 2,100 new team members and an attrition rate of approximately 21%[43] Health and Safety - The Recordable Injury Rate in 2023 was 0.74 per 100 employees, reflecting the company's commitment to health and safety[49] - The Recordable Injury Rate for the company in 2023 was 0.74 per 100 employees, reflecting its commitment to health and safety[49] Capital Expenditures - The company has not required material capital expenditures for compliance with government regulations in 2023 and does not expect significant expenditures in 2024[29] - The company has not incurred material capital expenditures for compliance with government regulations in 2023 and does not expect significant expenditures in 2024[29] Strategic Initiatives - The company continues to pursue strategic initiatives in drug containment components and novel drug delivery devices, focusing on innovation and market expansion[42] - The company continues to pursue strategic initiatives in drug containment components and integrated drug delivery systems, focusing on innovation and market expansion[42] Supply Chain Management - The company maintains a supply chain management strategy that relies on single-source suppliers for many critical raw materials, which increases supply chain risk[25] - The company maintains a supply chain management strategy that relies on single-source suppliers for many critical raw materials, which poses risks of supply interruption[25] Gender Demographics - The company has a global gender demographic of 64% men and 36% women among its employees as of December 31, 2023[43] - The company has a global gender demographic of 64% men and 36% women among its employees as of December 31, 2023[43] Environmental Commitment - The company is committed to environmental, social, and governance (ESG) initiatives, focusing on sustainability and community health[52] - The company has committed to a climate and greenhouse gas reduction strategy, focusing on renewable energy and sustainability in its operations[52] Market Presence - The company’s proprietary products are primarily sold to major biologic, generic, and pharmaceutical drug companies, indicating a strong market presence[33]

West Pharmaceutical Services, Inc. (NYSE:WST) Q4 2023 Earnings Conference Call February 15, 2024 9:00 AM ET Corporate Participants Quintin Lai - Vice President, Strategy and Investor Relations Eric Green - Chair, President and Chief Executive Officer Bernard Birkett - Senior VP and Chief Financial and Operations Officer Conference Call Participants David Windley - Jefferies Paul Knight - KeyBanc Capital Markets Jacob Johnson - Stephens Derik De Bruin - Bank of America Matt Larew - William Blair John Sourbee ...

Fourth-Quarter 2023 and Full Year Results WST Q4/FY 2023 Earnings 1 | --- | |-------------------------------------------------------------------------------| | Quarter Overall Net Sales $732.0M \| 3.3% | | | | Diluted Earnings Per Share: $1.83 Adjusted Diluted Earnings Per Share: $1.83 | "We had strong 2023 base organic sales growth, excluding the headwinds from lower pandemic- related sales, led by high-value product (HVP) components and devices and contract manufacturing. Our continued investments in both ...